Corvus Pharmaceuticals CRVS Offering Costs Accrued And Charged To Additional Paid In Capital
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept crvs:OfferingCostsAccruedAndChargedToAdditionalPaidInCapital.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's offering costs accrued and charged to additional paid in capital.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's offering costs accrued and charged to additional paid in capital?
- Corvus Pharmaceuticals (CRVS) reported offering costs accrued and charged to additional paid in capital of $553K in Q1 2026.